Publications

Rennert H, Eng K, Zhang T, Tan A, Xiang J, Romanel A, Kim R, Tam W, Liu Y-C, Bhinder B et al..  2016.  Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care.. NPJ Genom Med. 1

Gayvert KM, Dardenne E, Cheung C, Boland MRegina, Lorberbaum T, Wanjala J, Chen Y, Rubin MA, Tatonetti NP, Rickman DS et al..  2016.  A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors.. Cell Rep. 15(11):2348-56.

Vosoughi A, Zhang T, Shohdy KS, Vlachostergios PJ, Wilkes DC, Bhinder B, Tagawa ST, Nanus DM, Molina AM, Beltran H et al..  2020.  Common germline-somatic variant interactions in advanced urothelial cancer.. Nat Commun. 11(1):6195.

Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, Rosenberg J, Mosquera JMiguel, Robinson B, Elemento O et al..  2016.  Clonal evolution of chemotherapy-resistant urothelial carcinoma.. Nat Genet. 48(12):1490-1499.

Augello MA, Liu D, Deonarine LD, Robinson BD, Huang D, Stelloo S, Blattner M, Doane AS, Wong EWP, Chen Y et al..  2019.  CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.. Cancer Cell. 35(4):603-617.e8.

Augello MA, Liu D, Deonarine LD, Robinson BD, Huang D, Stelloo S, Blattner M, Doane AS, Wong EWP, Chen Y et al..  2019.  CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.. Cancer Cell. 35(5):817-819.

Fernandez EM, Eng K, Beg S, Beltran H, Faltas BM, Mosquera JMiguel, Nanus DM, Pisapia DJ, Rao RA, Robinson BD et al..  2019.  Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution.. JCO Precis Oncol. 3

Huang L, Fernandes H, Zia H, Tavassoli P, Rennert H, Pisapia D, Imielinski M, Sboner A, Rubin MA, Kluk M et al..  2017.  The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations.. J Am Med Inform Assoc. 24(3):513-519.

Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KSteve, Talenfeld AD, Nanus DM et al..  2018.  Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. Cancer. 124(5):1008-1015.